EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels

Rodolfo Hernández, Nipun Lakshitha de Silva, Jemma Hudson, Moira Cruickshank, Richard Quinton, Paul Manson, Waljit S Dhillo, Siladitya Bhattacharya, Miriam Brazzelli, Channa N Jayasena iD

Andrology · 2024

DOI: 10.1111/andr.13597 ↗

At a glance

Journal article in Andrology, 2024. Written by Rodolfo Hernández and 9 co-authors. Institution: Health Economics Research Unit, University of Aberdeen, Foresterhill, Aberdeen, UK. Major MEDLINE topics: Testosterone, Cost-Benefit Analysis, Hypogonadism, Randomized Controlled Trials as Topic. 47 references. The full text is freely available (open access, CC BY 4.0). Funded by: Health Technology Assessment programme, Medical Research Council, National Institute for Health and Care Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Testosterone is safe and highly effective in men with organic hypogonadism, but worldwide testosterone prescribing has recently shifted towards middle‐aged and older men, mostly with low testosterone related to age, diabetes and obesity, for whom there is less established evidence of clinical safety and benefit. The value of testosterone treatment in middle‐aged and older men with low testosterone is yet to be determined. We therefore evaluated the cost‐effectiveness of testosterone treatment in such men with low testosterone compared with no treatment.

Methods

A cost‐utility analysis comparing testosterone with no treatment was conducted following best practices in decision modelling. A cohort Markov model incorporating relevant care pathways for individuals with hypogonadism was developed for a 10‐year‐time horizon. Clinical outcomes were obtained from an individual patient meta‐analysis of placebo‐controlled, double‐blind randomised studies. Three starting age categories were defined: 40, 60 and 75 years. Cost utility (quality‐adjusted life years) accrued and costs of testosterone treatment, monitoring and cardiovascular complications were compared to estimate incremental cost‐effectiveness ratios and cost‐effectiveness acceptability curves for selected scenarios.

Results

Ten‐year excess treatment costs for testosterone compared with non‐treatment ranged between £2306 and £3269 per patient. Quality‐adjusted life years results depended on the instruments used to measure health utilities. Using Beck depression index‐derived quality‐adjusted life years data, testosterone was cost‐effective (incremental cost‐effectiveness ratio

Subjects

MeSH terms (MEDLINE)

TestosteroneCost-Benefit AnalysisHypogonadismRandomized Controlled Trials as TopicHumansMaleMiddle AgedAgedAdultQuality-Adjusted Life YearsHormone Replacement TherapyMarkov Chains

Author keywords

cost-effectivenesseconomic modehypogonadismtechnology assessmenttestosterone

Substances

Testosterone

Authors and institutions

  • Health Economics Research Unit, University of Aberdeen, Foresterhill, Aberdeen, UK.
  • Faculty of Medicine, General Sir John Kotelawala Defence University, Colombo, Sri Lanka.
  • Department of Metabolism, Digestion and Reproduction, Imperial College, London, UK.
  • Health Service Research Unit, University of Aberdeen, Aberdeen, UK.
  • Translational & Clinical Research Institute, University of Newcastle upon Tyne, Newcastle Upon Tyne, UK.
  • Department of Endocrinology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.

ORCID profiles: Channa N Jayasena

Funding

  • Health Technology Assessment programme
  • Medical Research Council
  • National Institute for Health and Care Research

Cite

APA

Hernández, R., de Silva, N. L., Hudson, J., Cruickshank, M., Quinton, R., Manson, P., Dhillo, W. S., Bhattacharya, S., Brazzelli, M., & Jayasena, C. N. (2024). Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels. Andrology. https://doi.org/10.1111/andr.13597

Vancouver

Hernández R, de Silva NL, Hudson J, Cruickshank M, Quinton R, Manson P, et al. Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels. Andrology. 2024. doi:10.1111/andr.13597

BibTeX
@article{Hernndez2024,
  author = {Hernández, Rodolfo and de Silva, Nipun Lakshitha and Hudson, Jemma and Cruickshank, Moira and Quinton, Richard and Manson, Paul and Dhillo, Waljit S and Bhattacharya, Siladitya and Brazzelli, Miriam and Jayasena, Channa N},
  title = {Cost‐effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels},
  journal = {Andrology},
  year = {2024},
  doi = {10.1111/andr.13597}
}
Start for free →